Stem Cells in Post-Stroke Regenerative Therapy: Current Role of Wharton’s Jelly Mesenchymal Stem Cells in the Orchestrum
Brain Sciences · 23.07.2026 · 16 (8) · 775
DOI: 10.3390/brainsci16080775 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Brain Sciences, online erschienen am 23.07.2026. Verfasst von Anastassiya Ganina und 7 weiteren Autor:innen. Beteiligte Einrichtung: JSC National Scientific Medical Center, 42 Abylay Khan Ave., Astana 010009, Kazakhstan. Die Arbeit nennt 285 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science Committee of the Ministry of Science and Higher Education of the Republic of Kazakhstan.
Themen: Schlaganfall
Abstract (Originalsprache)
Background/Objectives: Modern approaches for post-stroke rehabilitation cover mechanistically different ways—from physiotherapy to digital technologies. Among these approaches, stem cell-based therapy represents probably the most complex but promising strategy.
Methods
We discuss the current state-of-the-art of using mesenchymal stem cells (MSCs) in post-stroke regenerative therapy. Despite relatively wide use of bone marrow and adipose tissue MSCs, these cells represent a more mature (“adult”) state, which limits their proliferative and regenerative potentials. Compared to the “adult” MSCs, less “mature” MSCs obtained from umbilical cord, specifically Wharton’s jelly MSCs (WJ-MSCs), demonstrate unique functional capabilities and are free from certain technical and ethical issues.
Results
The molecular and cellular mechanisms of action of WJ-MSCs are thoroughly discussed in comparison with abundantly used “adult” types of MSCs. We also comparatively evaluate their preclinical and clinical application for treating post-stroke patients. Recent findings indicate that not only MSCs but also their secretome/exosomes (cell-free product) represent a therapeutically beneficial cellular drug in post-stroke recovery. Specially designed and carefully evaluated protocols, which preserve the bioactivity of the cell-free product intact, are mentioned. Neuroprotective and neuroreparative properties of cell-free products—secretome and exosomes—derived from Wharton’s jelly MSCs are summarized.
Conclusions
Cell-free products obtained from WJ-MSCs are an innovative adjunct therapy for post-stroke disorders, despite certain challenges and limitations of this type of therapy still present. By further investigation of the molecular composition and biological mechanisms of the WJ-MSC secretome and exosomes, their clinical applicability in neuroinflammatory and neurodegenerative pathologies will be promoted.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- JSC National Scientific Medical Center, 42 Abylay Khan Ave., Astana 010009, Kazakhstan.
ORCID-Profile: Anastassiya Ganina, Naizabek Yerzhigit, Oleg Lookin
Förderung
- Science Committee of the Ministry of Science and Higher Education of the Republic of Kazakhstan
Zitieren
APA
Ganina, A., Yerzhigit, N., Lookin, O., Orassay, A., Shaimardanova, G., Chuvakova, E., Askarov, M., & Baigenzhin, A. (2026). Stem Cells in Post-Stroke Regenerative Therapy: Current Role of Wharton’s Jelly Mesenchymal Stem Cells in the Orchestrum. Brain Sciences, 16(8), 775. https://doi.org/10.3390/brainsci16080775
Vancouver
Ganina A, Yerzhigit N, Lookin O, Orassay A, Shaimardanova G, Chuvakova E, et al. Stem Cells in Post-Stroke Regenerative Therapy: Current Role of Wharton’s Jelly Mesenchymal Stem Cells in the Orchestrum. Brain Sciences. 2026;16(8):775. doi:10.3390/brainsci16080775
BibTeX
@article{Ganina2026,
author = {Ganina, Anastassiya and Yerzhigit, Naizabek and Lookin, Oleg and Orassay, Aliya and Shaimardanova, Galiya and Chuvakova, Elmira and Askarov, Manarbek and Baigenzhin, Abay},
title = {Stem Cells in Post-Stroke Regenerative Therapy: Current Role of Wharton’s Jelly Mesenchymal Stem Cells in the Orchestrum},
journal = {Brain Sciences},
year = {2026},
volume = {16},
number = {8},
pages = {775},
doi = {10.3390/brainsci16080775}
}
EUVIMED